Part of the preserved effect of SGLT-2 inhibition on body weight in CKD may therefore result from increased urinary sodium and electrolyte free-water excretion [70] (although non-renal effects centrally or in the gut cannot be excluded). The gene discussed is SLC5A2; the disease is chronic kidney disease.